Financial News with AI Impact Scores

Adobe shares are trading higher after the company beat Q4 earnings estimates and issued strong guidance.

XOMA Royalty Corporation shares are trading lower after partner Rezolute reported negative trial results for its partnered product, Ersodetug.

Google Faces EU Fine Next Year For Favouring Own Services, Sources Say – Reuters Exclusive

Google is expected to face a fine from the European Union next year for allegedly favoring its own services over competitors. This development follows ongoing scrutiny of the company's business practices in the region. The specific amount of the fine has not been disclosed, but it could have significant implications for Google's operations in Europe.

Google Faces EU Fine Next Year For Favouring Own Services, Sources Say – Reuters Exclusive

Google is expected to face a fine from the European Union next year for allegedly favoring its own services over competitors. This follows ongoing scrutiny and regulatory challenges the company has faced in the EU regarding its business practices. The potential financial impact of the fine has not been disclosed, but it could affect Google's operations and market position in Europe.

Anthony Scaramucci Is 'Not Chain Monogamous', Predicts Solana Will 'Flip' Ethereum

Anthony Scaramucci, founder of SkyBridge Capital, expressed his belief that Solana (SOL) could surpass Ethereum (ETH) in market value due to its rapid growth in developer activity, user base, and throughput capacity. He made these comments at Solana's Breakpoint conference, emphasizing that both networks can thrive simultaneously. Currently, Ethereum is trading around $3,203 after a breakout and retest pattern, while Solana is trading near $130, holding support between $129 and $133 despite a recent 4% drop.

Eli Lilly shares are trading higher after the company reported its Phase 3 TRIUMPH-4 trial of retatrutide met all primary and key secondary endpoints, showing significant weight loss and improved pain and physical function.

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $145

Needham analyst Joseph Stringer has maintained a 'Buy' rating on Rhythm Pharmaceuticals (NASDAQ: RYTM) and increased the price target from $120 to $145.

BTIG Maintains Buy on Warby Parker, Raises Price Target to $32

BTIG analyst Janine Stichter has maintained a 'Buy' rating on Warby Parker (NYSE: WRBY) and increased the price target from $25 to $32. This adjustment reflects a positive outlook on the company's performance.

Roivant Signals Major Pipeline Momentum With Accelerated Timelines

Roivant Sciences Ltd. (NASDAQ: ROIV) outlined its long-term vision during its Investor Day, highlighting accelerated timelines for several late-stage programs, with three first-in-class commercial launches expected within the next three years. The company is advancing its lead asset, brepocitinib, with a new drug application anticipated in early 2026 and a commercial launch in early 2027. Roivant's shares rose 7.26% to $21.71, reaching a new 52-week high.

Black Titan Releases DAT+ Liquidity and Operational Readiness Pillar For Institutional Digital Asset Assessment

Black Titan Corporation (NASDAQ: BTTC) has introduced the fifth pillar of its DAT+ framework, focusing on liquidity and operational criteria for assessing digital assets in institutional settings. The new pillar highlights the importance of deep and stable liquidity, on-chain transaction traceability, technological maturity for automation, and compatibility with corporate operations such as treasury and compliance.